Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
TERN Terns Pharmaceuticals Inc
- Stocks
- Healthcare
- NASDAQ: TERN
Price (delayed)
$3.83
Market cap
$334.5M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.08
Enterprise value
$196.72M
Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, or NASH, and other chronic liver
Highlights
Terns Pharmaceuticals's quick ratio has increased by 34% from the previous quarter and by 12% YoY
The company's EPS rose by 14% YoY and by 3.6% QoQ
Terns Pharmaceuticals's debt has soared by 189% YoY but it has decreased by 8% from the previous quarter
TERN's equity is up by 38% YoY but it is down by 6% QoQ
Key stats
What are the main financial stats of TERN
Market
Valuations
Earnings
Shares outstanding
87.34M
Market cap
$334.5M
Enterprise value
$196.72M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.03
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$103.85M
Net income
-$90.39M
EBIT
-$90.14M
EBITDA
-$89.31M
Free cash flow
-$71.67M
Per share
Balance sheet
Liquidity
EPS
-$1.08
EPS diluted
-$1.08
Free cash flow per share
-$0.78
Book value per share
$3.73
Revenue per share
$0
TBVPS
$3.71
Total assets
$339.32M
Total liabilities
$13.27M
Debt
$1.24M
Equity
$326.04M
Working capital
$326.81M
Debt to equity
0
Current ratio
30.89
Quick ratio
30.57
Net debt/EBITDA
1.54
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-27.5%
Return on equity
-28.8%
Return on invested capital
-59.6%
Return on capital employed
-27.4%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
TERN stock price
How has the Terns Pharmaceuticals stock price performed over time
Intraday
-4.25%
1 week
-1.79%
1 month
27.24%
1 year
-46.13%
YTD
-30.87%
QTD
38.77%
Financial performance
How have Terns Pharmaceuticals's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$103.85M
Net income
-$90.39M
Gross margin
N/A
Net margin
N/A
Price vs fundamentals
How does TERN's price correlate with its fundamentals
Growth
What is Terns Pharmaceuticals's growth rate over time
Valuation
What is Terns Pharmaceuticals stock price valuation
P/E
N/A
P/B
1.03
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The company's EPS rose by 14% YoY and by 3.6% QoQ
TERN's equity is up by 38% YoY but it is down by 6% QoQ
The price to book (P/B) is 31% lower than the 5-year quarterly average of 1.5 and 26% lower than the last 4 quarters average of 1.4
Efficiency
How efficient is Terns Pharmaceuticals business performance
TERN's ROIC is down by 26% YoY
The return on equity is up by 19% year-on-year and by 6% since the previous quarter
The company's return on assets rose by 19% YoY and by 5% QoQ
Dividends
What is TERN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for TERN.
Financial health
How did Terns Pharmaceuticals financials performed over time
The total assets is up by 38% YoY but it is down by 7% from the previous quarter
Terns Pharmaceuticals's quick ratio has increased by 34% from the previous quarter and by 12% YoY
Terns Pharmaceuticals's debt is 100% less than its equity
Terns Pharmaceuticals's debt has soared by 189% YoY but it has decreased by 8% from the previous quarter
TERN's equity is up by 38% YoY but it is down by 6% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.